The landscape of precision cancer medicine clinical trials in the United States

Cancer Treatment Reviews

Volumn 41, Issue 5, 2015, Pages 385-390

  Roper, Nitin ^a   Stensland, Kristian D ^b,c   Hendricks, Ryan ^b   Galsky, Matthew D ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Tisch Cancer Institute   (United States)

^c LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Actionable mutations; Clinical trials; Clinicaltrials.gov; Genomics; Precision cancer medicine; Precision medicine

Indexed keywords

BREAST CANCER; CANCER GENETICS; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; GENE MUTATION; GENOMICS; HUMAN; OPEN STUDY; PERSONALIZED MEDICINE; PRECISION CANCER MEDICINE; REVIEW; SKIN CANCER; UNITED STATES; GENETICS; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROCEDURES; TRENDS;

CLINICAL TRIALS AS TOPIC; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; NEOPLASMS; UNITED STATES;

EID: 84937511297     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2015.02.009     Document Type: Review

References (30)

1. Johansen Taber KA, Dickinson BD, Wilson M. The promise and challenges of next-generation genome sequencing for clinical care [Internet]. JAMA Intern Med 2014;174:275-80 [cited 2014 Apr 11]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24217348.
2. Committee on a Framework for Development a New Taxonomy of Disease & the National Research Council. Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease [Internet]; 2011. Available from: http://www.ucsf.edu/sites/default/files/legacy_files/documents/new-taxonomy.pdf.
3. Patients' Genes Seen as Future of Cancer Care - NYTimes.com [Internet]. Available from: http://www.nytimes.com/2013/04/22/health/patients-genes-seen-as-future-of-cancer-care.html?_r=0.
4. Meric-Bernstam F, Farhangfar C, Mendelsohn J, et al. Building a personalized medicine infrastructure at a major cancer center [Internet]. J Clin Oncol 2013;31:1849-57. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23589548.
5. Califf RM, Zarin DA, Kramer JM, et al. Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010 [Internet]. JAMA 2012;307:1838-47 [cited 2014 May 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22550198.
6. Van Allen EM, Wagle N, Stojanov P, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine [Internet]. Nat Med 2014;20:682-8 [cited 2014 May 23]. Available from: http://dx.doi.org/10.1038/nm.3559.
7. Palmer G.A., Miller V.A., Curran J., et al. Next-generation sequencing (NGS) to identify actionable genomic changes in common and rare solid tumors: the FMI experience with the initial 50 consecutive patients. J Clin Oncol 2012, 30.
8. Foundation One Gene List [Internet] [cited 2013 May 22]. Available from: http://foundationone.com/genelist1.php.
9. Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma [Internet]. Science 2011;333:1157-60 [cited 2014 Jul 16]. Available from: http://www.sciencemag.org.ezproxy.cul.columbia.edu/content/333/6046/1157.abstract?ijkey=bc19ebfd622c6d6ba1d99d6d0fe66ea81a29becd%26keytype2=tf_ipsecsha.
10. Stephens PJ, Tarpey PS, Davies H, et al. The landscape of cancer genes and mutational processes in breast cancer [Internet]. Nature 2012;486:400-4 [cited 2014 Jul 10]. Available from: http://www.nature.com.ezproxy.cul.columbia.edu/nature/journal/v486/n7403/full/nature11017.html.
11. Hodis E, Watson IR, Kryukov G V, et al. A landscape of driver mutations in melanoma [Internet]. Cell 2012;150:251-63 [cited 2014 Jul 11]. Available from: http://www.sciencedirect.com/science/article/pii/S0092867412007787.
12. Pao W, Girard N. New driver mutations in non-small-cell lung cancer [Internet]. Lancet Oncol 2011;12:175-80 [cited 2014 Jul 11]. Available from: http://www.sciencedirect.com/science/article/pii/S1470204510700875.
13. Weischenfeldt J, Simon R, Feuerbach L, et al. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer [Internet]. Cancer Cell 2013;23:159-70 [cited 2014 Sep 13]. Available from: http://www.sciencedirect.com/science/article/pii/S1535610813000044.
14. Network TCGA. Comprehensive molecular characterization of human colon and rectal cancer [Internet]. Nature 2012;487:330-7 [cited 2014 Jul 11]. Available from: http://www.nature.com.ezproxy.cul.columbia.edu/nature/journal/v487/n7407/full/nature11252.html.
15. Brugarolas J. Molecular genetics of clear-cell renal cell carcinoma [Internet]. J Clin Oncol 2014;32:1968-76 [cited 2014 Sep 24]. Available from: http://jco.ascopubs.org.ezproxy.cul.columbia.edu/content/32/18/1968.long.
16. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs [Internet]. JAMA 2014;311:1998-2006 [cited 2014 May 23]. Available from: http://jama.jamanetwork.com/article.aspx?articleid=1872815.
17. Gray SW, Hicks-Courant K, Cronin A, et al. Physicians' attitudes about multiplex tumor genomic testing [Internet]. J Clin Oncol 2014;32:1317-23 [cited 2014 Apr 30]. Available from: http://jco.ascopubs.org/content/32/13/1317.abstract?ijkey=6b14186aa497f14f24fb1c48f7dcbc913caccb13%26keytype2=tf_ipsecsha.
18. Hall MJ. Conflicted confidence: academic oncologists' views on multiplex pharmacogenomic testing [Internet]. J Clin Oncol 2014;32:1290-2 [cited 2014 May 20]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24663051.
19. Wagle N, Berger MF, Davis MJ, et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing [Internet]. Cancer Discov 2012;2:82-93 [cited 2014 Apr 30]. Available from: http://cancerdiscovery.aacrjournals.org/content/2/1/82.full.
20. El-Maraghi RH, Eisenhauer EA. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III [Internet]. J Clin Oncol 2008;26:1346-54 [cited 2014 Mar 13]. Available from: http://jco.ascopubs.org/content/26/8/1346.full?sid=e4aff37d-12fa-4f21-8490-8ade8d878b3b.
21. Sleijfer S, Bogaerts J, Siu LL. Designing transformative clinical trials in the cancer genome era [Internet]. J Clin Oncol 2013;31:1834-41 [cited 2013 Dec 11]. Available from: http://jco.ascopubs.org/content/31/15/1834.abstract?ijkey=2f269956204187ba151fa955d888e3efad1fc4c4%26keytype2=tf_ipsecsha.
22. Tajik P, Zwinderman AH, Mol BW, et al. Trial designs for personalizing cancer care: a systematic review and classification [Internet]. Clin Cancer Res 2013;19:4578-88 [cited 2014 Mar 13]. Available from: http://clincancerres.aacrjournals.org.ezproxy.cul.columbia.edu/content/19/17/4578.full.
23. Simon R, Roychowdhury S: Implementing personalized cancer genomics in clinical trials [Internet]. Nat Rev Drug Discov 2013;12:358-69 [cited 2014 Jan 25]. Available from: http://dx.doi.org/10.1038/nrd3979.
24. Kelloff GJ, Sigman CC. Cancer biomarkers: selecting the right drug for the right patient [Internet]. Nat Rev Drug Discov 2012;11:201-14 [cited 2014 Mar 20]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22322254.
25. Wagle N, Grabiner BC, Van Allen EM, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer [Internet]. N Engl J Med 2014;371:1426-33 [cited 2014 Oct 8]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25295501.
26. Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity [Internet]. Science 2012;338:221 [cited 2014 Apr 17]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3633467%26tool=pmcentrez%26rendertype=abstract.
27. Wagle N, Grabiner BC, Van Allen EM, et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib [Internet]. Cancer Discov 2014 [cited 2014 Mar 19]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24625776.
28. Sledge GW. The challenge and promise of the genomic era [Internet]. J Clin Oncol 2012;30:203-9 [cited 2014 Jun 5]. Available from: http://jco.ascopubs.org/content/30/2/203.long.
29. Sledge GW, Miller RS, Hauser R. CancerLinQ and the future of cancer care [Internet]. Am Soc Clin Oncol Educ Book 2013;430-4 [cited 2014 Jun 5]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23714566.
30. Section 801 Food and Drug Administration Amendments Act of 2007 [Internet]. Washington, DC. Available from: http://www.gpo.gov/fdsys/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf.